[{"orgOrder":0,"company":"Laboratoires des M\u00e9dicaments St\u00e9riles","sponsor":"Hopital Charles Nicolle","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase IV","graph3":"Laboratoires des M\u00e9dicaments St\u00e9riles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Laboratoires des M\u00e9dicaments St\u00e9riles \/ Hopital Charles Nicolle","highestDevelopmentStatusID":"11","companyTruncated":"Laboratoires des M\u00e9dicaments St\u00e9riles \/ Hopital Charles Nicolle"},{"orgOrder":0,"company":"Laboratoires des M\u00e9dicaments St\u00e9riles","sponsor":"University Hospital Fattouma Bourguiba","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Laboratoires des M\u00e9dicaments St\u00e9riles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Laboratoires des M\u00e9dicaments St\u00e9riles \/ University Hospital Fattouma Bourguiba","highestDevelopmentStatusID":"11","companyTruncated":"Laboratoires des M\u00e9dicaments St\u00e9riles \/ University Hospital Fattouma Bourguiba"},{"orgOrder":0,"company":"Laboratoires des M\u00e9dicaments St\u00e9riles","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Laboratoires des M\u00e9dicaments St\u00e9riles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Laboratoires des M\u00e9dicaments St\u00e9riles \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Laboratoires des M\u00e9dicaments St\u00e9riles \/ Undisclosed"},{"orgOrder":0,"company":"Laboratoires des M\u00e9dicaments St\u00e9riles","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Oncology","graph2":"Phase IV","graph3":"Laboratoires des M\u00e9dicaments St\u00e9riles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratoires des M\u00e9dicaments St\u00e9riles \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Laboratoires des M\u00e9dicaments St\u00e9riles \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Farmaceuticos Rovi","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase I","graph3":"Laboratorios Farmaceuticos Rovi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Farmaceuticos Rovi \/ PRA Health Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Laboratorios Farmaceuticos Rovi \/ PRA Health Sciences"},{"orgOrder":0,"company":"Thrombosis Research Institute","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Thrombosis Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Thrombosis Research Institute \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Thrombosis Research Institute \/ Sanofi"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"National Guard Health Affairs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SAUDI ARABIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Oncology","graph2":"Phase III","graph3":"National Guard Health Affairs","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Guard Health Affairs \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Guard Health Affairs \/ Undisclosed"},{"orgOrder":0,"company":"Valleywise Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Valleywise Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valleywise Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Valleywise Health \/ Undisclosed"},{"orgOrder":0,"company":"Yale University","sponsor":"Children's Hospital Colorado | Children's Hospital of Philadelphia | BJC HealthCare | Medical College of Wisconsin | Children's of Alabama | Golisano Children's Hospital | Maria Fareri Children's Hospital | Nationwide Children\u2019s Hospital | New York Presby","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Yale University \/ Children's Hospital Colorado | Children's Hospital of Philadelphia | BJC HealthCare | Medical College of Wisconsin | Children's of Alabama | Golisano Children's Hospital | Maria Fareri Children's Hospital | Nationwide Children\u2019s Hospital | New York Presby","highestDevelopmentStatusID":"9","companyTruncated":"Yale University \/ Children's Hospital Colorado | Children's Hospital of Philadelphia | BJC HealthCare | Medical College of Wisconsin | Children's of Alabama | Golisano Children's Hospital | Maria Fareri Children's Hospital | Nationwide Children\u2019s Hospital | New York Presby"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"St. David's HealthCare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"St. David's HealthCare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. David's HealthCare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"St. David's HealthCare \/ Undisclosed"},{"orgOrder":0,"company":"Intermountain Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Intermountain Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intermountain Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Intermountain Health \/ Undisclosed"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"IWK Health Centre | Children's Hospital of Philadelphia | Children's Hospital of Eastern Ontario","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ IWK Health Centre | Children's Hospital of Philadelphia | Children's Hospital of Eastern Ontario","highestDevelopmentStatusID":"10","companyTruncated":"Hamilton Health Sciences \/ IWK Health Centre | Children's Hospital of Philadelphia | Children's Hospital of Eastern Ontario"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Monash Medical Centre","sponsor":"Southern Health, Victoria | Eastern Health, Victoria | Royal Adelaide Hospital | Prince of Wales Hospital, Sydney | Christchurch Hospital, NZ | Auckland City Hospital | North Shore Hospital, New Zealand | Middlemore Hospital, New Zealand","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase IV","graph3":"Monash Medical Centre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monash Medical Centre \/ Southern Health, Victoria | Eastern Health, Victoria | Royal Adelaide Hospital | Prince of Wales Hospital, Sydney | Christchurch Hospital, NZ | Auckland City Hospital | North Shore Hospital, New Zealand | Middlemore Hospital, New Zealand","highestDevelopmentStatusID":"11","companyTruncated":"Monash Medical Centre \/ Southern Health, Victoria | Eastern Health, Victoria | Royal Adelaide Hospital | Prince of Wales Hospital, Sydney | Christchurch Hospital, NZ | Auckland City Hospital | North Shore Hospital, New Zealand | Middlemore Hospital, New Zealand"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III||heparin derivatives and low molecular weight (or depolymerized) heparins","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III||heparin derivatives and low molecular weight (or depolymerized) heparins","graph1":"Undisclosed","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Farma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bio Farma \/ Undisclosed"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase I","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Venus Remedies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Venus Remedies \/ Undisclosed"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Saint Etienne","sponsor":"CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Centre Hospitalier Universitaire de Saint Etienne","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Centre Hospitalier Universitaire de Saint Etienne \/ CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang","highestDevelopmentStatusID":"11","companyTruncated":"Centre Hospitalier Universitaire de Saint Etienne \/ CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang"},{"orgOrder":0,"company":"Pirogov Russian National Research Medical University","sponsor":"Medtronic Plc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Pirogov Russian National Research Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pirogov Russian National Research Medical University \/ Medtronic plc","highestDevelopmentStatusID":"1","companyTruncated":"Pirogov Russian National Research Medical University \/ Medtronic plc"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"RUSSIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Chemi SpA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ITALY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase I","graph3":"Chemi SpA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chemi SpA \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chemi SpA \/ Undisclosed"},{"orgOrder":0,"company":"Chemi SpA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ITALY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase I","graph3":"Chemi SpA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chemi SpA \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chemi SpA \/ Undisclosed"},{"orgOrder":0,"company":"Minapharm Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"EGYPT","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Minapharm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minapharm Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Minapharm Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Western University, Canada","sponsor":"Valeo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Western University, Canada","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Western University, Canada \/ Valeo Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Western University, Canada \/ Valeo Pharma"},{"orgOrder":0,"company":"Techdow USA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Techdow USA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Techdow USA \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Techdow USA \/ Undisclosed"},{"orgOrder":0,"company":"Techdow USA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Techdow USA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Techdow USA \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Techdow USA \/ Undisclosed"},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Meitheal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Meitheal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Meitheal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Desjardins Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Private Placement","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Valeo Pharma","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Valeo Pharma \/ Desjardins Capital Markets","highestDevelopmentStatusID":"15","companyTruncated":"Valeo Pharma \/ Desjardins Capital Markets"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Group Purchasing Organizations","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Valeo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valeo Pharma \/ Group Purchasing Organizations","highestDevelopmentStatusID":"15","companyTruncated":"Valeo Pharma \/ Group Purchasing Organizations"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Valeo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valeo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Valeo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Premier","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Undisclosed","graph3":"Meitheal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meitheal Pharmaceuticals \/ Premier","highestDevelopmentStatusID":"1","companyTruncated":"Meitheal Pharmaceuticals \/ Premier"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Undisclosed"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase II","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endeavor Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Health \/ Undisclosed"},{"orgOrder":0,"company":"Glasgow Caledonian University","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Glasgow Caledonian University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Glasgow Caledonian University \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Glasgow Caledonian University \/ Undisclosed"},{"orgOrder":0,"company":"Suzanne C. Cannegieter, MD PhD","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Suzanne C. Cannegieter, MD PhD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzanne C. Cannegieter, MD PhD \/ ZonMw","highestDevelopmentStatusID":"1","companyTruncated":"Suzanne C. Cannegieter, MD PhD \/ ZonMw"},{"orgOrder":0,"company":"Suzanne C. Cannegieter, MD PhD","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Suzanne C. Cannegieter, MD PhD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzanne C. Cannegieter, MD PhD \/ ZonMw","highestDevelopmentStatusID":"1","companyTruncated":"Suzanne C. Cannegieter, MD PhD \/ ZonMw"}]
Find Clinical Drug Pipeline Developments & Deals for 6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid
Details :
Lovenox (enoxaparin sodium) is a novel small molecule Antithrombin-III activator. It is an anticoagulant medicine indicated for the treatment of venous thromboembolism including deep vein thrombosis.
Details :
The agreement aims for the for the localization of the full range of its flagship market leader product, Clexane (enoxaparin sodium), used to prevent clots from getting bigger or stopping new clots from forming.
Details :
Redesca (Enoxaparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Liver Diseases.
Details :
Lovenox is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Infertility, Female.
Details :
Enoxaparin Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Details :
Enoxaparin Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.
Details :
Lovenox-Generic (enoxaparin sodium) is a Factor XI/XIa inhibitor with a Prefilled Syringes with 30mg, 40mg, 60mg, 80mg, 100mg, 120mg, and 150mg strengths low molecular weight heparin (LMWH), is an anticoagulant that helps to prevent thrombosis.
Details :
Enoxaparin sodium binds to antithrombin III, a serine protease inhibitor, forming a complex that irreversibly inactivates factor Xa, which is frequently used to monitor anticoagulation in the clinical setting.
Details :
Enoxaparin Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Details :
The net proceeds of the Offering and Concurrent Private Placement will be used to support commercial efforts related to the recently launched products (Redesca™, Enerzair®, and Atectura®).
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
